Changes in the relative expression of circulating microRNAs linked to bone metabolism in HIV-infected Individuals with low bone mass

Author(s):  
Maria Yavropoulou ◽  
Artemis Kolynou ◽  
Polyzois Makras ◽  
Lemonia Skoura ◽  
Sideris Nanoudis ◽  
...  
2016 ◽  
Vol 17 (1) ◽  
Author(s):  
Gabriella Császárné Gombos ◽  
Viktória Bajsz ◽  
Emese Pék ◽  
Béla Schmidt ◽  
Eszter Sió ◽  
...  

2007 ◽  
Vol 22 (10) ◽  
pp. 1518-1525 ◽  
Author(s):  
Eberhard Denk ◽  
Darren Hillegonds ◽  
Richard F Hurrell ◽  
John Vogel ◽  
Karin Fattinger ◽  
...  

2020 ◽  
Author(s):  
Zsofia Petho ◽  
Edit Kalina ◽  
Zoltan Pap ◽  
Katalin Hodosi ◽  
Rebeka Falcsik ◽  
...  

Abstract Background: Skeletal manifestations are predominant in psoriatic arthritis (PsA). The aim of this cross-sectional, case-controlled study is the complex assessment of areal and volumetric bone mineral density (BMD), fracture risk, vitamin D status and bone turnover markers, and its association with disease-related variables.Methods: Lumbar spine (L1-L4) and femur neck (FN) areal, and distal radius (DR) volumetric BMD, 10-year probability of major and hip osteoporotic fracture as assessed by the fracture risk assessment (FRAX) tool, markers of bone metabolism and disease activity were assessed.Results: Upon comparison of the disease and age- and sex-matched control groups, there was a statistically significant difference in FN areal (0.955±0.145 g/cm2 vs. 1.034±0.148 g/cm2; p=0.001) and DR total volumetric (285.7±61.8 mg/cm3 vs. 369.6±23.6 mg/cm3; p<0.001) BMD, 10 year probability for major osteoporotic (5.0% (0.7%-32%) vs. 3.5% (0%-17.5%); p=0.003) and hip (1.1% (0%-16%) vs. 0.5% (0%-6.1%); p=0.002) fracture and 25-hydroxyvitamin D status (53 (10-120) nmol/L vs. 67 (10-137; p<0.001) nmol/L). As compared to areal assessment, volumetric BMD measurements identified a significantly higher number of patients with low bone mass (T-Score £ -1.00) (34% vs. 88%, p<0.001). Upon multiple linear regression analysis, disease activity score, as determined by DAS28 assessment, was an independent predictor of 10-year probability for major osteoporotic fracture (B (95%CI) = 1.351 (0.379–2.323); p = 0.007).Conclusion: In the studied PsA cohort, disease activity was an independent predictor of 10-year probability for a major osteoporotic fracture, and complemented assessment of volumetric and areal BMD assured better efficacy at identifying those with low bone mass.


2014 ◽  
Vol 58 (5) ◽  
pp. 478-483 ◽  
Author(s):  
Robert Güerri-Fernández ◽  
Judit Villar-García ◽  
Adolfo Díez-Pérez ◽  
Daniel Prieto-Alhambra

With the advent of high active antiretroviral therapy there was a significant improvement on HIV subjects survival. Thus, bone changes related to HIV became an important aspect of these individuals. HIV affects bone remodeling causing bone fragility. In addition, antiretroviral therapy may also negatively affect bone metabolism. Several studies describe an increased incidence of fractures in these patients when compared with controls without the disease. The European Society of AIDS (EACS), and other societies, have included guidance on management of osteoporosis in HIV-infected patients emphasizing the identification of patients with low bone mass. Supplementation of calcium and vitamin D and the use of alendronate in these individuals should be recommended on a case base.


2005 ◽  
Vol 20 (5) ◽  
pp. 476
Author(s):  
Jung-Min Koh ◽  
Hee-Sook Lee ◽  
Duk Jae Kim ◽  
Ghi Su Kim

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1756.2-1756
Author(s):  
A. Nack ◽  
I. Casafont-Solé ◽  
L. Mateo ◽  
S. Holgado Pérez ◽  
M. Martínez-Morillo ◽  
...  

Background:There are several studies assessing bone mass and osteoporosis (OP) development of patients with giant cell arteritis (GCA) during glucocorticoid treatment, however data at time of diagnosis is scarce.Objectives:To analyze bone metabolism, bone mineral density (BMD) and trabecular microarchitecture by measuring trabecular bone score (TBS) in patients with recent diagnosis of GCA.Methods:Retrospective observational study in which we included all patients with GCA and bone metabolism assessment at diagnosis. We recorded: risk factors for OP (previous fractures and anti-OP treatments), bone metabolism (calcium, phosphate, PTH, 25-vitaminD [25-OHD]) and the DXA results (Lunar, DPX) at the time of diagnosis and during the follow-up. The statistic analysis was made with SPSS.Results:36 patients (27 W: 9M) with a mean age of 76±9 years were included. The clinical characteristics of the GCA at diagnoses were: headache (81%), constitutional syndrome (58%), allodynia (42%), visual loss (42%, binocular in 2 patients), jaw claudication (39%), polymyalgic syndrome (28%), amaurosis fugax (25%) and lingular necrosis (n=1, 3%). Additional diagnosis tests included: temporal biopsy (86%, being pathologic in 55%), temporal ultrasound (97%, pathologic 34%), extra-cranial arteries ultrasound (81%, pathologic 7%) and PET/CT (19%, pathologic 86%). Up to 61% received three metilprednisolone bolus (mean dose 1700mg). 7 patients (19%) had previous OP and 3 had already suffered a fragility fracture (Colles, vertebral and femur). Only 4 patients were receiving anti-OP treatment (2 oral bisphosphonate, 2 zoledronate).At time of diagnosis of GCA, the mean of 25OHD was 17±13ng/mL (88%, <30). BMD showed low bone mass in 80% of patients (47% with OP, 33% osteopenia). The mean TBS was 1.026±0.098 and up to 38% showed poor bone microarchitecture [values <1.23]). No significant differences were observed between patients with or without TBS <1.23. Up to 94% of patients received anti-OP treatment (26 zoledronate, 6 oral bisphosphonate, 1 denosumab, 1 teriparatide). 3 patients had incidental fractures during the follow-up, however no relation was found with BMD or TBS.Conclusion:Low bone mass and vitamin D insufficiency are frequent in patients with recent diagnoses of GCA and up to 38% have poor bone microarchitecture at baseline. Thus, it’s important to perform a bone mass assessment in all patients with recent diagnose of ACG and initiate therapeutic or preventive anti-OP treatment if required.Disclosure of Interests:None declared


Sign in / Sign up

Export Citation Format

Share Document